We are live on ! Find out more
TXMD icon

TherapeuticsMD
TXMD

46 hedge funds and large institutions have $3.54M invested in TherapeuticsMD in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

10% more funds holding

Funds holding: 42 → 46 (+4)

0.41% more ownership

Funds ownership: 28.13% → 28.55% (+0.41%)

6% less capital invested

Capital invested by funds: $3.78M → $3.54M (-$234K)

73% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 11

Holders
46
Holders Change
+4
Holders Change %
+9.52%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
11
Closed
3
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$60K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$38.4K
2
Renaissance Technologies
Renaissance Technologies
New York
+$23.1K
3
TSS
Two Sigma Securities
New York
+$1.72K
4
Barclays
Barclays
United Kingdom
+$49
5
Osaic Holdings
Osaic Holdings
Arizona
+$40

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$4.64K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$2.44K
3
Morgan Stanley
Morgan Stanley
New York
-$715
4
Raymond James Financial
Raymond James Financial
Florida
-$617
5
Simplex Trading
Simplex Trading
Illinois
-$480
Name Holding Trade Value Shares
Change 		Change in
Stake
RCMNY
1
Rubric Capital Management (New York)
New York
$1.28M – – –
CC
2
Clearline Capital
New York
$683K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$399K -$2.44K -2,173 -0.6%
TC
4
Tejara Capital
United Kingdom
$370K -$57 -51 -0%
ACM
5
ADAR1 Capital Management
Texas
$225K – – –
Morgan Stanley
6
Morgan Stanley
New York
$140K -$715 -638 -0.5%
BlackRock
7
BlackRock
New York
$125K – – –
Geode Capital Management
8
Geode Capital Management
Massachusetts
$116K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$38.2K +$23.1K +20,600 +138%
Citadel Advisors
10
Citadel Advisors
Florida
$36.3K +$38.4K +34,273 New
BCM
11
Bridgeway Capital Management
Texas
$36K – – –
State Street
12
State Street
Massachusetts
$31.9K – – –
Northern Trust
13
Northern Trust
Illinois
$17.7K – – –
JGC
14
J. Goldman & Co
New York
$14.6K – – –
TSS
15
Two Sigma Securities
New York
$12.9K +$1.72K +1,531 +15%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$8.79K – – –
TRCT
17
Tower Research Capital (TRC)
New York
$2.94K -$167 -149 -5%
Osaic Holdings
18
Osaic Holdings
Arizona
$972 +$40 +36 +4%
National Bank of Canada
19
National Bank of Canada
Quebec, Canada
$710 -$45 -40 -6%
UBS Group
20
UBS Group
Switzerland
$390 -$4.64K -4,140 -92%
JP Morgan Chase
21
JP Morgan Chase
New York
$310 – – –
SS
22
SBI Securities
Japan
$274 – – –
US Bancorp
23
US Bancorp
Minnesota
$264 – – –
BNP Paribas Financial Markets
24
BNP Paribas Financial Markets
France
$243 – – –
HNB
25
Huntington National Bank
Ohio
$129 – – –
1
2

TXMD Hedge Fund Activity: Q3 2025 in Review

46 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2025, worth a combined $3.54M — down 6.2% from $3.78M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new TXMD positions and 3 closed out — a net gain of 4 holders — while 3 added to existing stakes and 11 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $38.4K. The largest seller was UBS Group, cutting an estimated $4.64K.

  • 46 institutional investors held TherapeuticsMD (TXMD) as of Q3 2025, up from 42 in Q2 2025.
  • Funds reported $3.54M of TherapeuticsMD stock for Q3 2025, down 6.2% quarter-over-quarter.
  • 7 funds opened new TherapeuticsMD positions in Q3 2025 and 3 closed out, a net change of +4 holders.
  • The largest TherapeuticsMD buyer in Q3 2025 was Citadel Advisors, an estimated $38.4K added.
  • The largest TherapeuticsMD seller in Q3 2025 was UBS Group, an estimated $4.64K sold.

Based on aggregated 13F filings for Q3 2025.